1h Free Analyst Time
The DNA Sequencing Market grew from USD 21.27 billion in 2025 to USD 25.72 billion in 2026. It is expected to continue growing at a CAGR of 21.61%, reaching USD 83.69 billion by 2032. Speak directly to the analyst to clarify any post sales queries you may have.
Strategic overview of the rapidly evolving DNA sequencing ecosystem underpinning next-generation healthcare and biosciences
DNA sequencing has moved from a niche laboratory technique to a foundational technology reshaping medicine, agriculture, biosecurity, and environmental management. The ability to decode genetic information at scale is now central to how health systems approach diagnostics, how pharmaceutical companies discover and validate new targets, and how researchers interrogate complex biological systems. What began as the sequencing of individual genes has matured into comprehensive genomic, transcriptomic, and epigenomic profiling that informs decisions from the clinic to the farm.
This evolution has been driven by relentless improvements in throughput, accuracy, and cost efficiency across instruments, consumables, software, and services. High-throughput platforms, increasingly automated library preparation, and sophisticated bioinformatics workflows have collectively made it feasible to integrate sequencing into routine clinical and research workflows. At the same time, the ecosystem has diversified, with a spectrum of technologies from established Sanger sequencing to next-generation and third-generation platforms, each addressing distinct application and performance requirements.
As adoption broadens, the DNA sequencing market is becoming more structurally complex. End users now range from academic and government research labs to hospitals, diagnostic laboratories, pharmaceutical and biotechnology enterprises, and contract research organizations. Each of these stakeholders demands different combinations of hardware, reagents, data analytics, and support services. The result is a competitive landscape in which differentiation increasingly depends on ecosystem strength, workflow integration, and application-specific expertise rather than on hardware specifications alone.
Against this backdrop, regulatory expectations, data governance frameworks, and reimbursement policies continue to evolve. Clinical use of sequencing in oncology, infectious disease diagnostics, reproductive health, and rare disease testing is particularly sensitive to evidence requirements, quality standards, and payer acceptance. At the same time, societal awareness of genetic privacy and ethical considerations is shaping how data is collected, stored, and utilized across sectors.
This executive summary provides a strategic synthesis of the forces reshaping the DNA sequencing landscape. It examines transformative shifts in technology and business models, analyzes the implications of upcoming United States tariffs in 2025, highlights key segmentation insights across offerings, technologies, sample types, applications, and end users, and distills regional and competitive dynamics. It then concludes with actionable recommendations for industry leaders seeking to navigate uncertainty while capitalizing on the expanding role of sequencing in science, medicine, and industry.
Transformative shifts redefine DNA sequencing from standalone technologies to integrated, application-driven genomic ecosystems
The DNA sequencing sector is undergoing a structural transition characterized by convergence of high-throughput technologies, end-to-end workflow integration, and growing emphasis on clinical-grade reliability. Next-generation sequencing has firmly established itself as the backbone technology for large-scale genomic analysis, yet the market is no longer defined solely by throughput and cost per base. Instead, user priorities increasingly center on turnaround time, data interpretability, sample-to-answer automation, and the ability to integrate sequencing outputs with electronic health records, laboratory information systems, and broader data platforms.
One of the most notable shifts is the move from instrument-centric purchasing to platform and ecosystem thinking. Users now evaluate portfolios that span specialized consumables and reagents, such as enzymes, buffers, primers, probes, and sequencing kits, alongside tightly coupled instruments, including sequencers, library preparation systems, PCR machines, and flow cell or cartridge hardware. These components are expected to work seamlessly with bioinformatics software and services that manage data processing, variant calling, annotation, visualization, and reporting. As a result, competitive advantage is increasingly tied to system reliability, ease of use, and the flexibility to accommodate evolving applications rather than standalone equipment performance.
Another transformative trend is the rise of service-based models that lower barriers to sophisticated sequencing. Contract sequencing, data analysis services, and technical support and maintenance offerings now play a pivotal role in enabling organizations without extensive in-house infrastructure to deploy advanced genomics. This shift is especially apparent among smaller hospitals, emerging biotechnology companies, and resource-constrained laboratories that prefer variable operating expenditures over significant upfront capital investment. Over time, this service orientation is creating new opportunities for specialization in complex areas such as epigenetic sequencing, metagenomics, and whole-genome clinical interpretation.
Technological differentiation is also accelerating at the level of sequencing modalities. Traditional Sanger sequencing maintains a role in targeted validation and smaller-scale workflows, while next-generation sequencing dominates high-throughput applications through methods such as sequencing by synthesis, nanopore-based approaches, and ion semiconductor platforms. Third-generation sequencing technologies are gaining attention for their ability to generate long reads that resolve structural variants, complex genomic regions, and haplotypes, which are critical in areas like oncology, rare disease analysis, and microbial genomics. Epigenetic sequencing, enabled by bisulfite methods and chromatin immunoprecipitation-based approaches, is expanding the scope of genomics beyond static DNA sequences to include regulatory mechanisms and chromatin architecture.
Simultaneously, the diversity of sample types being sequenced is expanding. Human specimens ranging from blood, saliva, buccal swabs, urine, tissue, cell-free DNA, and plasma have become the foundation of clinical and translational applications, while plant, animal, microbial, and environmental samples support agrigenomics, veterinary medicine, industrial microbiology, and ecological surveillance. This variety is driving the need for robust, standardized protocols that can handle variable input quality and quantity without sacrificing data quality.
These technological and workflow shifts are occurring alongside a redefinition of value in the application space. Clinical diagnostics increasingly relies on multi-gene panels, exomes, and whole genomes for oncology, infectious disease detection, reproductive health screening, and newborn screening. Research applications have broadened to encompass genomics, transcriptomics, functional genomics, and epigenetics, with sequencing at the core of experimental design. Drug discovery and development now leverage sequencing for biomarker discovery, companion diagnostic development, and target identification and validation, while agrigenomics, forensics, and environmental metagenomics use sequencing to improve crop traits, resolve crime scene evidence, and monitor ecosystems.
Collectively, these shifts are transforming the DNA sequencing landscape from a set of discrete technology segments into an interconnected ecosystem that spans instruments, consumables, software, and services, with increasing emphasis on clinical impact, scalability, and integration into real-world decision-making processes.
Cumulative 2025 United States tariffs reshape DNA sequencing supply chains, cost structures, and strategic procurement choices
The evolving trade environment, particularly the anticipated cumulative impact of United States tariffs in 2025, is poised to influence cost structures, supply strategies, and competitive positioning across the DNA sequencing value chain. Many critical components, including sequencing instruments, optical and electronic subsystems, specialized polymers, enzymes, and other consumables, are sourced or manufactured through globally distributed supply networks. Any adjustment in tariff regimes can therefore ripple through equipment pricing, reagent costs, and service fees, influencing purchasing decisions among laboratories, hospitals, and research organizations.
Tariff increases on imported instruments and platforms, such as DNA sequencers, library preparation systems, PCR machines, and associated flow cell or cartridge hardware, could elevate capital acquisition costs in the United States. This would likely reinforce current trends toward leaning on contract sequencing services and shared core facilities, particularly for smaller institutions and emerging companies that may not be able to absorb higher upfront expenditures. Larger academic centers, pharmaceutical companies, and diagnostic laboratories may respond by re-evaluating equipment refresh cycles, consolidating vendors, or negotiating more comprehensive service and consumable agreements to offset cost pressures.
On the consumables and reagents side, tariffs applied to enzymes, buffers, primers, probes, and sequencing kits may exert incremental pressure on per-sample costs. While high-value clinical applications in oncology, infectious disease diagnostics, reproductive health, and rare disease testing are less price sensitive due to their critical nature, research-focused applications may experience more budget constraints. Laboratories might respond by optimizing library preparation protocols, increasing sample multiplexing, or adjusting sequencing depth to balance cost against data quality. Vendors, in turn, may accelerate efforts to localize manufacturing, redesign supply chains, and refine inventory strategies to minimize exposure to tariff-related volatility.
Tariff-driven uncertainty also intersects with strategic choices around technology adoption. Institutions evaluating transitions from established next-generation platforms to emerging third-generation or epigenetic sequencing technologies may weigh not only performance metrics and application fit but also exposure to trade-related risk. Systems that offer flexible reagent sourcing, compatibility with multiple consumable suppliers, or modular hardware may become more attractive in environments where tariff schedules are subject to revision.
In parallel, the services segment, including contract sequencing, bioinformatics and data analysis services, and technical support and maintenance, may experience a shift in demand patterns. Some service providers could face higher hardware and consumable costs, which might be reflected in pricing. However, organizations without the scale to negotiate directly with instrument vendors might still find outsourced models more economical than direct capital purchases, even under a less favorable tariff regime. This dynamic could further entrench the role of centralized sequencing hubs in the United States, particularly those with the capacity to amortize equipment costs across large project volumes.
While tariffs primarily impact import and export economics, they also encourage longer-term strategic responses such as regionalization of production, diversification of supplier bases, and hedging through multi-geography sourcing. For DNA sequencing companies, these considerations extend beyond manufacturing to encompass where to locate service centers, data processing infrastructure, and support personnel. Organizations that proactively adapt to the 2025 tariff environment by reinforcing supply chain resilience may achieve a competitive edge in pricing stability and reliability of supply.
Ultimately, the cumulative impact of United States tariffs in 2025 will not halt the expansion of DNA sequencing but will likely reconfigure how and where value is generated and captured. Stakeholders that comprehensively assess tariff exposure across instruments, consumables, software, and services, and that align procurement, manufacturing, and partnership strategies accordingly, will be better positioned to sustain growth while mitigating cost and supply risks.
Segmentation insights reveal diverse DNA sequencing demand drivers across offerings, technologies, samples, applications, and end users
Understanding the DNA sequencing market requires a nuanced view of how demand and innovation play out across offerings, technologies, sample types, applications, and end users. At the offerings level, the interplay between consumables and reagents, instruments and platforms, software, and services defines the economics of most deployments. Consumables and reagents, encompassing enzymes, buffers, primers, probes, and sequencing kits, represent the recurring revenue engine that underpins many business models. Instruments and platforms, including DNA sequencers, library preparation systems, PCR machines, and flow cell or cartridge hardware, serve as anchors that lock in users to specific reagent ecosystems. Meanwhile, software and bioinformatics solutions convert raw reads into clinically or scientifically actionable insights, and services such as contract sequencing, data analysis, and technical support provide flexibility for organizations that lack internal capacity or prefer operational expenditure models.
Technology type segmentation reveals distinct usage patterns and innovation pathways. Next-generation sequencing dominates large-scale genomic, transcriptomic, and metagenomic applications, with popular modalities such as sequencing by synthesis, nanopore-based systems, and ion semiconductor platforms competing on throughput, accuracy, read length, and cost. Sanger sequencing retains its foothold in confirmatory testing and smaller targeted workflows, particularly where regulatory familiarity and well-established protocols are important. Third-generation sequencing technologies, offering long-read capabilities, are emerging as critical tools for resolving structural variants, complex genomic regions, and phased haplotypes, and are gradually moving from specialized research into translational contexts. Epigenetic sequencing, including bisulfite-based approaches and methods such as chromatin immunoprecipitation sequencing, is opening new frontiers by enabling detailed interrogation of DNA methylation and chromatin state, which is essential for understanding gene regulation, cell identity, and disease mechanisms.
Segmentation by sample type underscores the breadth of biological questions addressed with sequencing. Human samples remain central, spanning blood, saliva and buccal swabs, urine, cell-free DNA, tissue, and plasma. These materials underpin clinical diagnostics, population genomics, and translational research. The growth of liquid biopsy approaches, which rely heavily on cell-free DNA and plasma, is particularly notable in oncology and prenatal testing. Beyond humans, animal samples support veterinary genomics and livestock improvement programs, while plant samples, including leaf, root, and seed, enable agrigenomic applications focused on yield, resilience, and trait discovery. Microbial samples, encompassing bacteria, viruses, fungi, and archaea, as well as environmental samples from soil, water, and air, are central to metagenomics, pathogen surveillance, and ecosystem monitoring, all of which have gained prominence following global infectious disease events and heightened awareness of zoonotic risks.
Application segmentation highlights how sequencing is increasingly embedded in diverse decision-making contexts. In clinical diagnostics, sequencing-based assays now inform oncology treatment selection, infectious disease diagnosis through pathogen identification and resistance profiling, rare disease and genetic disorder testing via exome or genome analysis, and reproductive health through prenatal testing and newborn screening. Research applications continue to push the boundaries of discovery across genomics and transcriptomics, functional genomics, and epigenetics research, with sequencing as a core experimental tool. Drug discovery and development rely on sequencing for biomarker discovery, companion diagnostic development, and target identification and validation, enabling more efficient and personalized therapeutic pipelines. In agrigenomics, sequencing supports plant breeding and trait discovery and crop pathogen surveillance, contributing to food security and climate resilience. Forensics and security leverage sequencing for human identification, criminal investigation, and disaster victim identification, while environmental and metagenomic studies apply sequencing to characterize complex microbial communities and track environmental change.
End user segmentation reveals differentiated purchasing behaviors and requirements. Academic and research institutions, including government research institutes and university labs, prioritize flexibility, method development, and access to cutting-edge technologies, often balancing internal capabilities with external services. Contract research organizations typically focus on scalability, throughput, and regulatory-compliant workflows to serve pharmaceutical and biotechnology clients. Hospitals and diagnostic laboratories must align sequencing operations with clinical accreditation standards, turnaround time expectations, and reimbursement constraints, favoring reliable, automated, and validated solutions. Pharmaceutical and biotechnology companies integrate sequencing throughout the drug development continuum, from discovery to clinical trials, and often require secure, compliant data management infrastructure alongside sequencing platforms.
Taken together, these segmentation insights illustrate that the DNA sequencing market is not a monolith but a heterogeneous network of specialized needs and value propositions. Suppliers that tailor offerings to specific technology preferences, sample types, applications, and end user requirements, while maintaining interoperability and robust support, are positioned to capture the most strategically significant opportunities.
Regional perspectives highlight divergent DNA sequencing adoption trajectories across the Americas, EMEA, and Asia-Pacific
Regional dynamics shape how DNA sequencing technologies are adopted, scaled, and integrated into healthcare and research infrastructures. In the Americas, strong investment in biomedical research, a robust biotechnology and pharmaceutical ecosystem, and a growing emphasis on precision medicine combine to create a fertile environment for sequencing innovation. Extensive networks of academic medical centers, cancer institutes, and specialized research hospitals drive high utilization of next-generation and emerging third-generation platforms for oncology, rare disease, and infectious disease applications. Regulatory frameworks increasingly recognize sequencing-based diagnostics, and payer systems are gradually expanding coverage for clinically validated genomic tests, particularly where clear evidence of clinical utility and cost-effectiveness exists.
Within the Americas, many hospitals, diagnostic laboratories, and research institutions have built substantial internal sequencing capabilities, supported by sophisticated bioinformatics infrastructure. At the same time, contract sequencing providers and core facilities play an important role in consolidating demand, enabling smaller institutions and emerging biotechnology firms to access advanced technologies without heavy capital investment. This regional environment encourages competition among instrument manufacturers, reagent suppliers, software developers, and service providers, fostering rapid innovation but also intensifying pressure to demonstrate differentiating value.
In Europe, the Middle East, and Africa, adoption patterns are more heterogeneous due to variations in healthcare systems, research funding levels, and regulatory maturity. Western European countries have been early adopters of clinical sequencing, leveraging national genomics initiatives and strong public-sector funding to embed sequencing into cancer care, rare disease diagnostics, and population-level research projects. Robust data protection regulations influence how genomic data is stored, shared, and integrated with clinical records, prompting investment in secure, interoperable informatics platforms. In parts of the Middle East, strategic national investments in healthcare modernization and life sciences are spurring the establishment of genomic medicine centers and large-scale sequencing projects, while in many African countries, sequencing capacity is expanding through regional hubs and international collaborations focused on infectious disease surveillance, antimicrobial resistance, and locally relevant genetic studies.
The Asia-Pacific region is emerging as one of the most dynamic arenas for DNA sequencing expansion, driven by rapid economic development, growing healthcare expenditure, and large, genetically diverse populations. Countries in this region are investing heavily in genomics research, biobanking, and precision medicine programs, which in turn stimulate demand for high-throughput sequencing platforms, consumables, and data analysis capabilities. Academic and clinical centers in key markets are adopting cutting-edge technologies not only for oncology and rare disease diagnostics but also for infectious disease monitoring, agrigenomics, and agricultural biotechnology. The region is also home to several influential sequencing technology developers and reagent manufacturers, reshaping global competitive dynamics and contributing to more localized innovation.
Across all three regions, environmental and metagenomic applications, forensic uses, and agricultural genomics are gaining prominence alongside traditional clinical and research uses. However, differences in regulatory environments, reimbursement mechanisms, and infrastructure readiness mean that the pace and nature of adoption vary significantly. Organizations seeking to expand globally must therefore adapt product portfolios, pricing strategies, and partnership models to regional specifics, aligning with local clinical priorities, research agendas, and policy frameworks.
Competitive landscape insights show DNA sequencing leaders differentiating through integrated workflows, services, and informatics
The competitive landscape in DNA sequencing is defined by a mix of established technology leaders, specialized innovators, and rapidly scaling regional players, each targeting different points along the value chain. Instrument manufacturers continue to compete intensely on throughput, accuracy, and cost per run, but the battleground has shifted toward complete workflow solutions that integrate sample preparation, sequencing, data processing, and interpretation. Companies offering tightly coupled systems of sequencers, library preparation instruments, and dedicated reagents are consolidating their positions by emphasizing reliability, automation, and regulatory-ready performance.
In parallel, a growing cohort of companies is focused on next-generation and third-generation platforms that differentiate through read length, real-time sequencing capabilities, and portability. These firms often target niche but expanding segments such as long-read structural variant analysis, field-deployable sequencing for outbreak response, and high-resolution microbial genomics. Their success hinges on demonstrating clear application advantages over incumbent short-read technologies, as well as building robust ecosystems of consumables, software, and service partnerships.
Software and bioinformatics companies have emerged as critical enablers within the DNA sequencing market. They address bottlenecks in data processing, storage, and interpretation through scalable pipelines, cloud-based platforms, and specialized algorithms for variant calling, annotation, and reporting. Increasingly, these players are embedding artificial intelligence and machine learning to support more accurate variant classification, automated report generation, and predictive modeling, particularly in oncology and rare disease contexts. Integration with clinical information systems and compliance with data protection and health information regulations are key differentiators in this space.
Service providers occupy another vital segment of the competitive landscape. Contract sequencing organizations, which offer project-based or long-term sequencing services, cater to a wide spectrum of customers from academic labs to large pharmaceutical firms. Their value propositions center on access to high-end instruments without capital expenditure, rapid turnaround times, and the ability to manage complex, multi-omics projects. Complementing these are bioinformatics and data analysis service companies that help clients transform raw sequence data into actionable insights, along with technical support and maintenance providers that ensure uptime and performance across installed instrument fleets.
Competition is also intensifying around application-specific solutions. In clinical diagnostics, companies are building integrated offerings that combine targeted or comprehensive sequencing assays, interpretation software, and quality-managed laboratory processes to support oncology, infectious disease, reproductive health, and rare disease testing. For drug discovery and development, specialized firms provide sequencing-based biomarker discovery services, companion diagnostic co-development, and support for sequencing-enabled clinical trials. In agrigenomics, forensics, and environmental genomics, niche players focus on tailored panels, assay designs, and workflows optimized for non-human or mixed samples.
Mergers, acquisitions, and strategic partnerships continue to shape the competitive landscape, as larger companies seek to fill gaps in their portfolios and smaller innovators leverage alliances to scale. Collaborations between instrument manufacturers and pharmaceutical companies, between bioinformatics providers and hospital systems, and between sequencing service organizations and academic consortia are common. These relationships help align technology development with real-world application needs and accelerate the translation of sequencing advances into clinical and commercial impact.
Ultimately, companies that succeed in this environment tend to share several characteristics: a strong technology foundation, a clear understanding of specific customer segments, robust quality and regulatory frameworks, and the ability to deliver integrated, end-to-end solutions. As the market matures, competitive differentiation will increasingly depend on demonstrating measurable improvements in outcomes, efficiency, and user experience rather than solely on incremental technical specifications.
Actionable strategies for DNA sequencing leaders to integrate workflows, de-risk supply chains, and accelerate application-driven growth
Industry leaders navigating the DNA sequencing landscape need to align strategic priorities with the evolving demands of healthcare systems, research communities, and regulatory bodies. One of the most actionable priorities is to invest in end-to-end workflow integration rather than isolated product enhancements. This means designing solutions where instruments, consumables, software, and services work together to deliver reliable, reproducible results with minimal manual intervention. For organizations supplying reagents, platforms, or software, this may involve deeper collaboration with complementary players to ensure interoperability from sample collection through to data interpretation and reporting.
Another critical recommendation is to strengthen resilience against supply chain and tariff-related disruptions. Companies should assess their dependence on specific geographies for manufacturing and sourcing of components such as sequencer hardware, optical modules, enzymes, and specialized consumables. Diversifying suppliers, localizing production where feasible, and maintaining strategic inventories for high-demand reagents can reduce vulnerability to trade policy shifts and logistics constraints. Transparent communication with customers about supply continuity and contingency planning can also reinforce trust and long-term relationships.
Leaders should also prioritize targeted innovation aligned with high-value applications. In clinical diagnostics, this includes focusing on assays and workflows that directly address current pain points in oncology, infectious disease, reproductive health, and rare disease diagnosis, while meeting rigorous regulatory and quality requirements. In drug discovery and development, sequencing providers can create differentiated value by integrating biomarker discovery, companion diagnostic development, and data analytics tailored to clinical trial needs. For agrigenomics, environmental genomics, and forensics, application-specific panels and optimized protocols can help unlock growth among specialized user communities.
Investment in informatics and data governance should be considered non-negotiable. As sequencing output grows, so does the complexity of data management, security, and interpretation. Organizations should enhance their capabilities in cloud-enabled analysis pipelines, secure storage, and compliant data sharing. Incorporating machine learning and advanced analytics into variant classification, metagenomic profiling, and multi-omics integration can improve both the speed and quality of decision-making. At the same time, strong governance frameworks are essential to address privacy, consent, and regulatory expectations across different jurisdictions.
In parallel, end user education and support merit increased attention. The expansion of sequencing into community hospitals, smaller laboratories, and non-traditional settings means that many users require practical guidance on assay selection, workflow optimization, quality control, and data interpretation. Industry leaders can build loyalty and differentiation by offering training programs, technical consultation, and ongoing performance optimization support, helping customers realize the full value of their sequencing investments.
Finally, organizations should remain actively engaged with policy-makers, regulatory authorities, and standard-setting bodies. Participation in guideline development, proficiency testing programs, and quality assurance initiatives allows industry stakeholders to shape realistic and scientifically grounded requirements for clinical and research sequencing. This engagement not only helps ensure that regulations keep pace with technology but also positions companies as trusted partners in the broader transformation of healthcare and life science research.
By executing on these recommendations-workflow integration, supply chain resilience, application-focused innovation, informatics investment, user support, and policy engagement-industry leaders can strengthen their competitive position and contribute meaningfully to the responsible expansion of DNA sequencing across sectors.
Robust research methodology integrating secondary evidence, stakeholder insights, and structured analysis of DNA sequencing dynamics
A rigorous research methodology underpins the insights presented in this executive summary, combining structured secondary research, targeted primary engagement, and systematic analytical frameworks. The objective is to provide an accurate and balanced view of the DNA sequencing landscape across offerings, technologies, sample types, applications, end users, and regions, while reflecting current industry realities and emerging trends.
Secondar.
Table of Contents
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
7. Cumulative Impact of Artificial Intelligence 2025
8. DNA Sequencing Market, by Offerings
9. DNA Sequencing Market, by Technology Type
10. DNA Sequencing Market, by Sample Type
11. DNA Sequencing Market, by Application
12. DNA Sequencing Market, by End User
13. DNA Sequencing Market, by Region
14. DNA Sequencing Market, by Group
15. DNA Sequencing Market, by Country
17. China DNA Sequencing Market
18. Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
The key companies profiled in this DNA Sequencing market report include:- 10x Genomics, Inc.
- Abbott Laboratories
- AbbVie Inc.
- Agilent Technologies, Inc.
- Azenta, Inc.
- Becton, Dickinson and Company
- BGI Genomics Co., Ltd.
- Bio-Rad Laboratories, Inc.
- BioChain Institute Inc.
- Charles River Laboratories International, Inc.
- Danaher Corporation
- Eppendorf SE
- Eurofins Scientific SE
- F. Hoffmann-La Roche Ltd.
- Genomics England
- Genscript Biotech Corporation
- Illumina, Inc.
- Johnson & Johnson Services, Inc.
- Laboratory Corporation of America Holdings
- Macrogen Inc.
- Merck KGaA
- Myriad Genetics, Inc.
- Novartis AG
- Novogene Co, Ltd.
- Oxford Nanopore Technologies PLC
- Pacific Biosciences of California, Inc.
- PerkinElmer, Inc.
- QIAGEN N.V.
- Sartorius AG
- Shimadzu Corporation
- Thermo Fisher Scientific Inc.
- Twist Bioscience Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 199 |
| Published | January 2026 |
| Forecast Period | 2026 - 2032 |
| Estimated Market Value ( USD | $ 25.72 Billion |
| Forecasted Market Value ( USD | $ 83.69 Billion |
| Compound Annual Growth Rate | 21.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 33 |
